局部晚期直肠癌患者避免局部复发的策略
本研究纳入105例局部晚期直肠癌患者,接受TS-1联合伊立替康的新辅助放化疗后行根治性手术,病理完全缓解率为23.8%,5年无复发生存率为79.3%,5年总生存率为87.1%。多因素分析显示性别、治疗前肿瘤直径、组织病理学治疗反应和ypN是无复发生存率的独立预测因素,仅ypN是总生存率的独立预测因素。作者认为联合TS-1与伊立替康以提高放射敏感性的治疗策略具有高缓解率。
要点
- 新辅助放化疗方案为盆腔放疗45 Gy分25次5周,同步S-1 80 mg/m2用25天,伊立替康60 mg/m2每周一次连续静脉输注。
- 病理完全缓解率为23.8%,5年无复发生存率79.3%,5年总生存率87.1%。
- 仅ypN是总生存率的独立预测因素(ypN1: p=0.0009;ypN2: p=0.0012)。
核心结论
- 作者认为联合TS-1与伊立替康以提高放射敏感性的治疗策略具有高缓解率。
研究设计与样本
- 研究纳入105例接受新辅助放化疗后行根治性手术的局部晚期直肠癌患者。
- 新辅助放化疗包括盆腔放疗45 Gy分25次5周,同步S-1 80 mg/m2用25天,伊立替康60 mg/m2每周一次连续静脉输注。
- 根治性手术在治疗后8周进行。
主要发现
- 病理完全缓解率为23.8%。
- 5年无复发生存率为79.3%,5年总生存率为87.1%。
- 多因素分析显示无复发生存率的独立预测因素包括性别(男性:p=0.0172)、治疗前肿瘤直径(<40 mm:p=0.0223)、组织病理学治疗反应(grade 0,1:p=0.0169)和ypN(ypN1:p=0.1995;ypN2:p=0.0007)。
- 仅ypN是总生存率的独立预测因素(ypN1:p=0.0009;ypN2:p=0.0012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To clarify the short- and long-term outcomes of radical surgery after neoadjuvant chemoradiotherapy (NCRT) with TS-1 and irinotecan, which enhances radiosensitivity, in patients with locally advanced rectal cancer. METHODS: The study group comprised 105 patients with locally advanced rectal cancer who received NCRT followed by radical surgery. NCRT consisted of pelvic radiotherapy (45 Gy in 25 fractions over a period of 5 weeks), S-1 (80 mg/m2) given concurrently for 25 days, and irinotecan (60 mg/m2), given once a week as a continuous intravenous infusion. Radical surgery was performed 8 weeks after treatment. RESULTS: A pathological complete response was confirmed in 23.8%. The 5-year recurrence-free survival rate was 79.3%, and the 5-year overall survival rate was 87.1%. Multivariate analysis showed that the following 4 variables were independent predictors of recurrence-free survival: Sex (male: p = 0.0172), Pre-treatment tumor diameter (< 40 mm: p = 0.0223), Histopathological treatment response (grade 0,1: p = 0.0169), and ypN (ypN1: p = 0.1995; ypN2: p = 0.0007). Only ypN was an independent predictor of overall survival (ypN1: p = 0.0009; ypN2: p = 0.0012). CONCLUSIONS: Our treatment strategy combining TS-1 with irinotecan to increase radiosensitivity had a high response rate.
引用
- Nakamura T, Sato T, Hayakawa K, et al. Strategy to avoid local recurrence in patients with locally advanced rectal cancer. Radiat Oncol. 2019. PMID: 30917848. doi:10.1186/s13014-019-1253-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。